ClinicalTrials.gg
RecruitingNCT07269041iTILTUpdated Mar 12, 2026

Immune Tolerance Induction After Liver Transplantation

A Phase 1/2 interventional study of Donor Hematopoietic Stem and Progenitor Cell Infusion in Liver Transplantation, Immune Tolerance and Immune Tolerance/Drug Effects, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by University of California, Los Angeles · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in End Stage Liver Disease with a site in United States — 9 open to participants now, 15 under way, none of them phase 3. End Stage Liver Disease · United States.

Planned enrollment
40th of 48
12 · median 64
Started
2026
with 1 other
Phase 1/2
2 of 66
1 open now
Primary completion
2029-01
later than 12 of 14 live
Registered
65th of 66
by date
Lead sponsor
3 of 66
University of California, Los Angeles

Among the 66 studies in End Stage Liver Disease with a site in United States, this one is the 40th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, reaches primary completion later than 12 of the 14 other live ones, and was the 65th registered.

End Stage Liver Disease

155 studies on the registry are indexed under End Stage Liver Disease; 31 are open to participants now.

Browse End Stage Liver Disease studies →

Open to participants now

9 of the 66 studies in End Stage Liver Disease with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 End Stage Liver Disease studies recruiting now, 14 (67%) set no upper age limit and 6 (29%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in End Stage Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed Tolerance" approach, achieving success in numerous kidney recipients now living drug-free. The process uses a conditioning regimen followed by donor stem cell infusion to retrain the immune system to accept the liver as "self."

Read the detailed description

This study seeks to determine if patients with a pre-existing, well-functioning liver transplant from an HLA-matched living donor can be withdrawn from maintenance immunosuppressive medications without compromising allograft function through hematopoietic stem and progenitor cell (HSPC) infusion from the same donor. HSPC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG) that takes course over two weeks, with HSPC infusion being on the final day. This entire protocol will take place in the outpatient setting.

At serial time points, (1) graft function will be monitored, (2) chimerism will be measured in recipient whole blood and white blood cell subsets, and (3) protocol biopsies of the graft will be obtained. An attempt will be made to discontinue tacrolimus. Weaning of tacrolimus will begin at 6 months with a goal of discontinuation by 10-12 months as long as the following conditions are met: (1) donor chimerism is detectable for at least 180 days after HSPC infusion, (2) stable graft function (defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and total bilirubin (TBil) levels each ≤ 2.0 × the upper limit of normal) is maintained without clinical or biopsy-determined rejection episodes, and (3) there is no evidence of graft-versus-host disease . HSPC infusion will consist of a target dose of 10 x106 CD34+ cells/kg and 5 x106 CD3+ cells/kg with the goal of achieving durable mixed chimerism.

Immunological tolerance through combined solid organ and HSPC transplant has been demonstrated at a few centers of excellence within the United States, including UCLA. The aim of these protocols is to liberate patients from lifelong immunosuppression. Thus far, protocols have been largely limited to HLA-matched donor recipient pairs undergoing simultaneous kidney and HSPC transplant from the same donor. In all protocols, the recipient undergoes a conditioning regimen to facilitate HSPC engraftment. At UCLA, our protocol employs a conditioning regimen of TLI and ATG. We are the first center to demonstrate the feasibility of retroactive immune tolerance, where a patient with a pre-existing fully HLA-matched kidney transplant underwent HSPC infusion following a conditioning regimen of TLI and ATG over one year after the kidney transplant surgery and successfully achieved durable mixed chimerism and tolerance, allowing permanent discontinuation of immunosuppressants - a process called "delayed tolerance."

Though the liver has intrinsic tolerogenic properties, tolerance protocols for liver are largely limited by the medical and logistical demands of recovering from liver transplant. As we have demonstrated in our single center experience, delayed tolerance has potential to be a reproducible strategy to permanently discontinue immunosuppressants in recipients who receive HSPC transplant months to years after transplant surgery. As such, recipients of HLA-matched living-donor liver transplants who have recovered from their surgery may benefit from protocols to establish tolerance and liberate them from lifelong immunosuppression.

03

Conditions studied

  • Liver Transplantation
  • Immune Tolerance
  • Immune Tolerance/Drug Effects
  • Graft Survival
  • Hematopoietic Stem Cell
  • Chimerism
  • Immunosuppression After Liver Transplantation
  • Immunosuppression Disorders
  • End Stage Liver Disease

Keywords

  • Liver Transplantation
  • Immune Tolerance
  • Hematopoietic Stem Cell Infusion
  • Chimerism
  • Mixed Chimerism
  • Total Lymphoid Irradiation
  • Antithymocyte Globulin
  • Immunosuppression Withdrawal
  • Living Donor Liver Transplant
  • Tolerance Induction
  • Delayed Immune Tolerance
  • Retroactive Immune Tolerance
  • Immunosuppression Toxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Recipient Inclusion Criteria:

  1. Males and females ages 18 years and older with a pre-existing liver transplant from a living donor with a donor-recipient match at 6 or more out of 12 alleles across the HLA-A, -B, -C, -DR, -DQ, and -DP loci, as determined by high-resolution HLA typing.
  2. Pre-existing living-donor liver transplant must be 12 months to 20 years from date of scheduled HSPC infusion.
  3. Agreement to participate in the study and ability to give .
  4. Liver within 4 weeks of enrollment without signs of rejection.
  5. Meets institutional criteria for HSPC infusion.
  6. Resides or is willing to stay within 3 hours distance from UCLA Medical Center by ground transportation for the first three months of the trial at the physician's discretion.
  7. No known to administration of rATG or radiation therapy.
  8. If subject is a female of (i.e., no documented absence of ovaries or uterus, history of tubal ligation, or status), subject must be confirmed not pregnant by a serum or urine pregnancy test and must agree to practice a reliable form of including hormonal treatments, barrier methods or intrauterine device for at least 12 months following initiation of the tolerance protocol.

Recipient Exclusion Criteria:

  1. Major ABO incompatibility with donor.
  2. Any of the following labs > 2.0 times the on screening: , ALT, ALP, GGT or TBil.
  3. History of rejection with current HLA-matched liver transplant within the last year.
  4. History of following liver transplant.
  5. Positive Class II HLA Donor-Specific Antibody (DSA) or class I DSA specificity above 5,000 MFI at the time of the stem cell infusion.
  6. History of multi-organ transplantation, either simultaneous or as separate events.
  7. History of more than one liver transplant.
  8. Known allergy to rabbit proteins.
  9. History of a major post-transplant complication at investigator discretion.
  10. History of active within the past 5 years except for:

    1. Malignancy that has not required treatment in the past on active surveillance.
    2. Malignancy treated with curative intent with no known active disease >2 years before the first dose of study treatment and of low potential risk for recurrence.
    3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    4. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, DCIS).
  11. Active bacterial, fungal or mycobacterial infection.
  12. viremia from EBV, CMV, or PCR test within the past 3 months.

    1. Significant CMV viremia is defined as greater than or equal to 137 IU/mL.
    2. If CMV low-level viremia is detected, defined as 137 - 1,000 IU/mL, patients may undergo subsequent testing up to twice per week and two consecutive negative results will allow for inclusion.
  13. Seropositivity for 1 or 2 by 4th generation serum antibody/antigen testing, or HTLV I or II by serum antibody testing.
  14. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  15. Active extra-hepatic disease requiring .
  16. Autoimmune disease was the indication for liver transplantation.
  17. Any condition that precludes the ability to give informed consent and/or places the subject at high risk for non-compliance with the safety monitoring requirements of the study.
  18. Received immunotherapy drugs, such as (e.g. pembrolizumab, nivolumab, and ipilimumab), tumor necrosis factor inhibitors, rituximab, or interleukin-2 within six months of the study treatment.
  19. Use of medications with known hepatotoxicity or potential to confound interpretation of liver function tests (e.g., methotrexate, isoniazid, amiodarone), unless reviewed and approved by the Principal Investigator and hepatology, and the subject has demonstrated stable liver function tests for ≥6 months while on the medication.
  20. Active hepatobiliary and pancreatic diseases:

    1. History of chronic hepatobiliary or pancreatic disorders that may interfere with safety assessments or interpretation of protocol endpoints, including but not limited to primary sclerosing cholangitis (PSC), autoimmune hepatitis, primary biliary cholangitis (PBC), chronic pancreatitis, recurrent cholangitis, biliary strictures, biliary obstruction, untreated bile duct injury, hepatobiliary malignancy, or metabolic/genetic liver disease (e.g., Wilson's disease, alpha-1 antitrypsin deficiency).
    2. Active chronic liver diseases such as metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease.
    3. Gallbladder diseases such as cholecystitis or symptomatic cholelithiasis.

Donor Inclusion Criteria:

  1. Males and females ages 18 years and older meeting the HLA-matching requirements specified in the "Recipient Inclusion Criteria" above.
  2. Must meet the following criteria for HSPC donation:

    1. : > 11 g/dl
    2. Plt: > 80,000/µL
    3. WBC: > 3,000/µL

Donor exclusion criteria:

  1. Major ABO incompatibility with recipient.
  2. Medically unfit to tolerate peripheral blood apheresis (e.g., small body size, poor vascular access, not a suitable candidate for placement of a central catheter).
  3. Pregnant (confirmed by urine or serum pregnancy test) or lactating.
  4. Seropositivity for HIV 1 or 2 by 4th generation serum antibody/antigen testing, HTLV I or II by serum antibody testing.
  5. Active West Nile Virus infection.
  6. Active bacterial, fungal, mycobacterial or viral infection (including active hepatitis B and/or C).
  7. Psychiatric, addictive, neurological, or other disorder that compromises ability to give true informed consent for participation in this study
  8. Use of oral anticoagulants within two days of apheresis.
  9. History of active malignancy within the past 5 years except for:

    1. Malignancy that has not required treatment in the past on active surveillance.
    2. Malignancy treated with curative intent with no known active disease >2 years before the first dose of study treatment and of low potential risk for recurrence.
    3. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    4. Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ, DCIS).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Tolerance Induction Arm

    Adult recipients with a pre-existing, well-functioning HLA-matched living-donor liver transplant from the same donor will undergo outpatient conditioning with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG), followed by infusion of mobilized donor hematopoietic stem and progenitor cells (separate CD34+ and CD3+ fractions). After HSPC infusion, participants will be monitored for donor chimerism, graft function, rejection, and GVHD, and will undergo a structured taper of maintenance immunosuppression with the goal of complete withdrawal if donor chimerism is present and protocol criteria are met.

    Biological: Donor Hematopoietic Stem and Progenitor Cell Infusion

Interventions

  • BiologicalDonor Hematopoietic Stem and Progenitor Cell Infusion

    Participants with a pre-existing, well-functioning HLA-matched living-donor liver transplant from the same donor will receive a delayed infusion of donor-derived hematopoietic stem and progenitor cells (HSPCs). Donors undergo mobilization and apheresis to collect peripheral blood stem cells, which are processed to generate a CD34+ cell product with an accompanying defined CD3+ T-cell dose. Recipients receive outpatient conditioning with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG) prior to infusion. The goal of the intervention is to induce tolerance by achieving durable mixed chimerism and enable structured withdrawal of maintenance immunosuppression.

    Also known as: Donor HSPC Infusion

06

What researchers measure

Primary outcomes

  1. Percentage of subjects weaned off liver transplant immunosuppressants at 12 months after HSPC infusion

    The percentage of subjects who successfully discontinue all liver transplant immunosuppressant medications at 12 months after HSPC infusion.

    Time frame: 12 months post-HSPC infusion.

Secondary outcomes

  1. Liver graft rejection within 48 months post-HSPC infusion

    Percentage of subjects with liver graft rejection within 48 months after HSPC infusion, defined as: 1. meeting Banff criteria for rejection on biopsy obtained to confirm clinical suspicion, or 2. clinical suspicion of rejection with response to corticosteroids when biopsy is contraindicated or declined.

    Time frame: Up to 48 months post-HSPC infusion.

  2. Graft failure

    Percentage of subjects with graft failure as determined by re-listing for liver transplantation and/or re-transplantation.

    Time frame: Up to 48 months post-HSPC infusion.

  3. Incidence of GVHD

    Incidence of graft-versus-host disease (GVHD) defined as grade ≥2 acute GVHD or score ≥2 chronic GVHD.

    Time frame: Up to 48 months post-HSPC infusion.

Other outcomes

  1. Chimerism persistence

    Percentage of subjects with detectable donor-recipient chimerism for at least 180 days within the first 12 months after HSPC infusion, and at 12, 24, 36, and 48 months.

    Time frame: 12, 24, 36, and 48 months post-HSPC infusion.

  2. Incidence of acute or chronic GVHD (detailed)

    Percentage of subjects that experienced acute or chronic GVHD, diagnosed clinically and/or by biopsy of the affected organ.

    Time frame: Up to 48 months post-HSPC infusion

  3. Liver function

    Percentage of subjects with normal liver function tests (AST, ALT, ALP, TBil, and GGT each ≤ 2× upper limit of normal) at 12, 24, 36, and 48 months.

    Time frame: 12, 24, 36, and 48 months post-HSPC infusion.

  4. Infection burden

    Mean number of bacterial, fungal, and viral infections per subject at 12, 24, 36, and 48 months.

    Time frame: 12, 24, 36, and 48 months post-HSPC infusion.

  5. Change in medication use for metabolic syndrome

    Percentage and average change in dosing of subjects requiring medications for hypertension, diabetes, and hyperlipidemia at Months 6, 12, 24, 36, and 48.

    Time frame: 6, 12, 24, 36, and 48 months post-HSPC infusion.

  6. Quality of Life as Assessed by Change from Baseline in PROMIS-29 Profile v2.1 Through Month 48

    The Patient-Reported Outcomes Measurement Information System 29-Item Profile v2.1 (PROMIS-29 Profile v2.1) is a validated 29-item patient-reported outcome measure assessing physical, mental, and social health in liver transplant recipients. Domains include physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social roles.

    Time frame: Baseline, Day 14, and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 36, and 48 post-HSPC infusion

  7. Quality of Life as Assessed by Change from Baseline in MTSOSD-R 59 Through Month 48

    Modified Transplant Symptom Occurrence and Symptom Distress Scale - Revised (MTSOSD-R 59) is a transplant-specific symptom inventory that assesses symptom occurrence and associated distress in immunosuppressed liver transplant recipients across multiple domains.

    Time frame: Baseline, Day 14, and Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, and 48 post-HSPC infusion

  8. Quality of Life as Assessed by Change from Baseline in pLTQ Through Month 48

    Post-Liver Transplant Quality of Life Instrument (pLTQ) is a liver transplant-specific quality-of-life instrument assessing physical, psychological, and social functioning domains relevant to long-term transplant outcomes.

    Time frame: Baseline, and Months 6, 12, 24, 36, and 48 post-HSPC infusion

07

Study locations

1 of 1 sites recruiting
  • UCLA Health 200 Medical Plaza
    Los Angeles, California 90095, United States
    Recruiting
    • Cray V. Noah, MD · Contactcnoah@mednet.ucla.edu · 310-267-7727
    • Ruth Jones · Contacttolerance@mednet.ucla.edu · 424-402-9564
    • Jeffrey Veale, MD · Principal investigator
    • Cray V. Noah, MD · Sub investigator
    • Caspian Oliai, MD · Sub investigator
    • Ann Raldow, MD · Sub investigator
    • Jasleen Singh, MD · Sub investigator
    • Samer Ebaid, MD, PhD, MS · Sub investigator
08

References and documents

Publications

  • Nassiri N, Lum E, Mead MD, Raldow AC, Kogut N, Veale JL. Immune tolerance induction through haematopoietic chimerism after kidney donation. Lancet. 2022 Aug 6;400(10350):e2. doi: 10.1016/S0140-6736(22)00914-X. No abstract available. PubMed 35934008 ↗
  • Lum EL, Nassiri N, Kogut N, Oliai C, Raldow A, Reed EF, Veale JL. Delayed immune tolerance through donor haematopoietic stem cell infusion 14 months after kidney transplantation. Lancet. 2024 Oct 5;404(10460):1346. doi: 10.1016/S0140-6736(24)01935-4. No abstract available. PubMed 39368842 ↗

Individual participant data

Plan to share: No — IPD will not be shared because this is a Phase I, single-site study involving transplant recipients and their living donors, where data elements such as HLA high-resolution typing, chimerism profiles, and longitudinal graft function measurements are inherently identifiable. Sharing raw IPD would pose a significant re-identification risk and is not permitted under the study's IND, IRB approval, or institutional policies for early-phase cellular therapy trials. Aggregate, de-identified results will be disseminated through scientific publications and presentations, but participant-level datasets will not be made publicly available.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 8, 2025
StartActual
Feb 20, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2033
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07269041
Responsible party
Cray V. Noah, MD (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Dec 8, 2025
Start date
Feb 20, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2033 (estimated)
Last update
Mar 12, 2026

Study contacts

Cray V. Noah, MD
Contact
cnoah@mednet.ucla.edu
310-267-7727
Ruth Jones
Contact
tolerance@mednet.ucla.edu
424-402-9564
Jeffrey Veale, MD
principal investigator · UCLA Health
Cray V. Noah, MD
study director · UCLA Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion